USCAP 2024: Automated classification of breast lesions using an AI-based approach

Back

This study, conducted at the Ohio State University Wexner Medical Center, demonstrated high performance for Ibex’s Galen Breast in detecting invasive and in situ breast carcinoma and correctly classifying benign cases. This AI solution went beyond cancer, accurately identifying multiple pathologies, such as lobular neoplasia, and other benign lesions, underscoring the potential of AI-based solutions for accurate classification of breast lesions, which is pivotal for effective clinical decision-making and patient management.

Back

About IBEX

IBEX is the leader in AI-powered cancer diagnostics in pathology. We empower physicians to provide every patient with an accurate, timely and personalized cancer diagnosis. Our AI platform is deployed worldwide, supporting pathologists and providers with AI-insights that help improve the quality and accuracy of diagnosis, reduce turnaround times and boost productivity.

By providing my details I agree to the IBEX-AI Terms and conditions and Privacy policy. I also agree to receive emails form IBEX-AI and I understand that I may opt out of IBEX-AI subscriptions at any time.

About IBEX

IBEX is the leader in AI-powered cancer diagnostics in pathology. We empower physicians to provide every patient with an accurate, timely and personalized cancer diagnosis. Our AI platform is deployed worldwide, supporting pathologists and providers with AI-insights that help improve the quality and accuracy of diagnosis, reduce turnaround times and boost productivity.

By providing my details I agree to the IBEX-AI Terms and conditions and Privacy policy. I also agree to receive emails form IBEX-AI and I understand that I may opt out of IBEX-AI subscriptions at any time.
Articles

How is artificial intelligence rising to the challenge in breast cancer diagnosis?

Articles

How ‘game-changing’ AI is helping discover cancer for the first time in UK | ITV News

Videos

The AI revolution in cancer diagnostics with Joseph Mossel, CEO of Ibex Medical Analytics